Akorn expands oral drug deal with Natco
US-based sterile specialty pharmaceuticals manufacturer Akorn has expanded its purchase and supply agreement with Natco Pharma, of Hyderabad, India, in order to commercialise a third oral drug product for the treatment of cancer.
US-based sterile specialty pharmaceuticals manufacturer Akorn has expanded its purchase and supply agreement with Natco Pharma, of Hyderabad, India, in order to commercialise a third oral drug product for the treatment of cancer.
The drug product is indicated for the treatment of advanced breast cancer in post-menopausal women as a first-line therapeutic agent. The current market size for this drug product is approximately US$490 million. Natco will be responsible for the development and manufacturing of the drug product, while Akorn will be responsible for marketing and distribution in the hospital, clinic, and home healthcare markets in Canada and the US.
Arthur Przybyl, Akorn's president and ceo, said: 'We are pleased to continue to expand our partnership with Natco Pharma. This oral anti-cancer product fits well with Akorn's overall strategy in the oncology arena. These select oral products are complementary to our generic injectable anti-cancer pipeline being developed with the Serum Institute of India.'
'We are pleased that the association with Akorn has been extended to cover a new product indicated for the treatment of advanced breast cancer as well,' said Natco Pharma's ceo Rajeev Nannapaneni.
'We are sure that, NATCO and Akorn together, in course of time, will become significant market players in the Oncology segment,' Nannapaneni added.